IBD

HEALWELL AI Announces New Commercial Agreements with WELL HEALTH USA and Circle Medical, Bringing AI-Based Preventative Care Solutions to U.S. Market

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, CRH, Algorithm, Partnership, Risk, EMR, Patient, SAN, Artificial intelligence, AI, WELL, Inflammatory bowel disease, IBD, TSX, OTCQX, Clinical trial, Strategic alliance, AIDX, Medical device

HEALWELL AI has signed services agreements with both WELL Health USA and U.S. based Circle Medical Technologies Inc., which expands its footprint in the U.S. and will enable U.S. healthcare providers with a suite of artificial intelligence (AI) powered preventative care solutions.

Key Points: 
  • HEALWELL AI has signed services agreements with both WELL Health USA and U.S. based Circle Medical Technologies Inc., which expands its footprint in the U.S. and will enable U.S. healthcare providers with a suite of artificial intelligence (AI) powered preventative care solutions.
  • HEALWELL’s Khure Health will integrate its proprietary AI platform with Circle Medical’s electronic medical record system, expanding its footprint to over 30 US states.
  • Enabling WELL USA and Circle Medical providers is a demonstration of this commitment and a major step forward for HEAWELL into the US market.
  • George Favvas, CEO of Circle Medical commented, “We are excited to partner with Khure and bring their AI solutions to the healthcare practitioners we support.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Thursday, March 14, 2024
Patient, LLP, Prescription, IBD, Investor's Business Daily, Amylyx Pharmaceuticals, Advertising, Court, BBC World Service, Evercore, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, March 13, 2024
Apoptosis, Patient, AMX0035, Science, P.C, Prospectus, Initiative, Form, Public expenditure, Scientific misconduct, IBD, Graphite, Safety, Data management, EAF, Reuters, Register, Food, Cassava Sciences, ALS, Alzheimer's disease, Uber, Defendant, Journal, Amyotrophy, News, Prescription, IPO, Particulates, Amylyx Pharmaceuticals, FDA, Sustainable development, DoorDash, Health, Environment, City University, Biomarker, Electrode, Cassava, Complaint, GrafTech, Investor's Business Daily, Neurobiology of Aging, Cognition, Government, BBC World Service, Evercore, Pharmaceutical industry

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference

Retrieved on: 
Wednesday, April 3, 2024
Managed Care, Research, Radiology, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, Other Science, Conference, Medicine, Patient, UC, RNA, IBD, Inflammatory bowel disease, Ulcerative colitis, Therapy, Pharmaceutical industry

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.

Key Points: 
  • Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.
  • The data showcases the potential predictive capabilities of Geneoscopy’s noninvasive stool RNA biomarker technology in informing therapeutic response for patients with inflammatory bowel disease (IBD).
  • Our participation at IBD Innovate reaffirms our commitment to advancing precision immunology for patients with IBD."
  • The research examined stool-derived eukaryotic RNA (seRNA) to predict therapeutic response and disease activity in Crohn’s Disease (CD) and Ulcerative Colitis (UC).

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Retrieved on: 
Monday, March 25, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AbbVie, Ulcerative colitis, Growth, I&I, Cell, ACG, Patient, ABBV, UC, Journal, Biomarker, NIMML, Acquisition, LANCL2, IPO, SLE, Personalized medicine, Volunteering, A.I, IBD, Medicine, Rheumatoid arthritis, Epithelium, DRS, Invention, Therapy, NLRX1, Work, Pharmaceutical industry

and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.

Key Points: 
  • and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.
  • “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades.
  • In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines.
  • Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

DNAnexus to Showcase the Power of High-Value Multi-Omics Data at the Precision Medicine in IBD Summit

Retrieved on: 
Monday, March 18, 2024
Hardware, Health Technology, Data Management, Technology, Nanotechnology, Pharmaceutical, General Health, Professional Services, Genetics, Biotechnology, Science, Software, Data Analytics, Internet, Research, Health, Cloud, Drug discovery, Tissue, RNA, Acquisition, Personalized medicine, IBD, Medicine, Inflammatory bowel disease, CLIA, Ecosystem, Ovation, Whole genome sequencing, Privacy, Pharmaceutical industry

The company is hosting a luncheon presentation that will focus on its collaboration with Ovation , an omics data company committed to accelerating the development of precision medicine, to help streamline large-scale omics data analysis.

Key Points: 
  • The company is hosting a luncheon presentation that will focus on its collaboration with Ovation , an omics data company committed to accelerating the development of precision medicine, to help streamline large-scale omics data analysis.
  • DNAnexus’ collaboration is initially focused on Ovation’s inflammatory bowel disease omics data, which includes whole genome sequencing and RNA sequencing on normal and diseased tissues linked to longitudinal clinical data.
  • Ovation’s omics data is derived from its extensive biobank of more than 1.6 million consented samples.
  • The secure and scalable DNAnexus Precision Health Data Cloud helps researchers manage, analyze, and collaborate on the complex multimodal data.

Advanced Infliximab Model Now Available from DoseMe

Retrieved on: 
Friday, March 15, 2024
Technology, Research, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Data Management, Science, Inflammatory bowel disease, Risk, Infliximab, IBD, Patient, Immunoglobulin G, BCPS, Doctor of Pharmacy, Inflammation, Vaccine

DoseMe , a leading provider of model-informed precision dosing, today announced the availability of its Infliximab model.

Key Points: 
  • DoseMe , a leading provider of model-informed precision dosing, today announced the availability of its Infliximab model.
  • Infliximab (IFX) is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody protein that contains both murine and human components that inhibit tumor necrosis factor-alpha(TNFα).
  • "We continue to enhance our models, and this model may predict infliximab concentration in patients with anti-drug antibodies,” added Roy.
  • “Both the learning set and validation set of this model had a large diversity in an indication of the patients, thus making this model especially equipped to dose infliximab for many indications.”
    For more information and an overview of all models currently available, visit https://doseme-rx.com/why-dosemerx/drug-packages

Global Irritable Bowel Disease (IBD) Market Analysis Report 2024: Increasing Prevalence of Crohn's Disease, and Ulcerative Colitis Driving the $21 Billion Market - Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
General Health, Pharmaceutical, Health, Corticosteroid, TNF, Injection (medicine), Growth, Prevalence, Porter's five forces analysis, Incidence, SWOT, Disease, Research, IBD, Market, Medicine, Crohn's disease, Route of administration, Ulcerative colitis, USD, Administration, JAK, Irritable bowel syndrome, Pharmaceutical industry

The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.

Key Points: 
  • The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.
  • The increasing incidence and prevalence of Crohn's Disease, and Ulcerative Colitis are major drivers for the growth of the Market.
  • The report analyses the Irritable Bowel Disease Market by Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes)
    The report analyses the Irritable Bowel Disease Market By Route of Administration (Injectable, Oral).
  • The report analyses the Irritable Bowel Disease Market by Indication (Crohn's Disease, Ulcerative Colitis).

Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions

Retrieved on: 
Tuesday, March 12, 2024
Software, Biotechnology, Pharmaceutical, General Health, Health, Health Technology, Technology, Apps, Applications, Partnership, Patient, Irritable bowel syndrome, Acquisition, CBT, Heartburn, Digestate, IBD, Bayer, Patient satisfaction, Cognitive behavioral therapy, Therapy, IBS, Lux Capital, FDA, Digestive, Coeliac disease, Gesellschaft mit beschränkter Haftung, Nursing

Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.

Key Points: 
  • Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.
  • The acquisition of Cara Care is expected to accelerate Mahana’s market entry in Europe where the reimbursement of digital programs is outpacing the United States.
  • Cara Care’s IBS prescription-based digital program is currently being prescribed, and reimbursed, to thousands of patients in Germany.
  • "The combination of Mahana and Cara Care is an incredible opportunity to bring together our complementary expertise in chronic digestive health conditions and create a one-of-a-kind global offering of digital programs across the Digestive, Hearing, Dermatology, and Women’s Health markets.

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Retrieved on: 
Wednesday, March 27, 2024
Community, Patient, Colostomy, Health care, Bacteria, Quality of life, Shoe, Curriculum, Western world, Abdominal pain, IBD, Immune system, Diarrhea, Disease, Health professional, Crohn's disease, Student, Environment, Caregiver, Incidence, Empathy, Abdomen, Inflammatory bowel disease, HY

DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE. The initiative, focused on raising awareness of the difficult symptoms of Inflammatory Bowel Disease (IBD), entailed an immersive 24-hour simulation that generated a deeper understanding of how the disease affects the daily lives of patients.

Key Points: 
  • DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE.
  • While inflammation is the body's natural reaction to irritation or injury, in patients with IBD, it is thought that the body's own immune system mistakenly identifies a harmless food or bacteria within the gut as 'foreign' and attacks it3.
  • Using a mobile app and an 'IBD kit,' participants engaged in common struggles, gaining insights into the disease's physical and emotional challenges.
  • Although the simulation couldn't fully replicate the experience, it is meant to foster empathy for individuals living with IBD.